Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).~* Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and delivery must have occurred on or after January 1, 2008 and on or before March 31, 2010~* Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin~Exclusion Criteria:~* Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.~* The following supplements within 2 months of diagnosis of pregnancy: B12 injection; \> 35mg Iron; \> 1.2 mg of folate; or a L-methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®~* History of leukemia or any anemia other than iron deficiency anemia or;~* Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Arm #1 (Test Group) (Type: None): 100 subject administered Neevo® or NeevoDHA® daily
- Arm #2 (Control group) (Type: None): 100 subject administered a prenatal vitamin daily

Based on this trial design, predict the completion outcome and termination type (if applicable).